Michael Buljan

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background Recent data from immune checkpoint studies, including studies of anti-PD1 and anti-PDL1 antibodies, suggest that an inflammatory intratumoral milieu is required for an optimal response to immune therapy. Serial biopsy analyses from a phase 1 study demonstrate that transformation of tumor cells with electroporation (EP) of plasmid interleukin-12(More)
  • 1